Literature DB >> 25145583

4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.

Chunmei Wang1, Antonio Cigliano, Lijie Jiang, Xiaolei Li, Biao Fan, Maria G Pilo, Yan Liu, Bing Gui, Marcella Sini, Jeffrey W Smith, Frank Dombrowski, Diego F Calvisi, Matthias Evert, Xin Chen.   

Abstract

UNLABELLED: Concomitant expression of activated forms of v-akt murine thymoma viral oncogene homolog (AKT) and Ras in mouse liver (AKT/Ras) leads to rapid tumor development through strong activation of the mammalian target of rapamycin complex 1 (mTORC1) pathway. mTORC1 functions by regulating p70S6K/ribosomal protein S6 (RPS6) and eukaryotic translation initiation factor 4E-binding protein 1/ eukaryotic translation initiation factor 4E (4EBP1/eIF4E) cascades. How these cascades contribute to hepatocarcinogenesis remains unknown. Here, we show that inhibition of the RPS6 pathway by rapamycin effectively suppressed, whereas blockade of the 4EBP1/eIF4E cascade by 4EBP1A4, an unphosphorylatable form of 4EBP1, significantly delayed, AKT/Ras-induced hepatocarcinogenesis. Combined treatment with rapamycin and 4EBP1A4 completely inhibited AKT/Ras hepatocarcinogenesis. This strong antineoplastic effect was successfully recapitulated by ablating regulatory associated protein of mTORC1, the major subunit of mTORC1, in AKT/Ras-overexpressing livers. Furthermore, we demonstrate that overexpression of eIF4E, the proto-oncogene whose activity is specifically inhibited by 4EBP1, resulted in hepatocellular carcinoma (HCC) development in cooperation with activated Ras. Mechanistically, we identified the ectonucleoside triphosphate diphosphohydrolase 5/ adenylate kinase 1/cytidine monophosphate kinase 1 axis and the mitochondrial biogenesis pathway as targets of the 4EBP1/eIF4E cascade in AKT/Ras and Ras/eIF4E livers as well as in human HCC cell lines and tissues.
CONCLUSIONS: Complete inhibition of mTORC1 is required to suppress liver cancer development induced by AKT and Ras proto-oncogenes in mice. The mTORC1 effectors, RPS6 and eIF4E, play distinct roles and are both necessary for AKT/Ras hepatocarcinogenesis. These new findings might open the way for innovative therapies against human HCC.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25145583      PMCID: PMC4280310          DOI: 10.1002/hep.27396

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

Review 1.  Eukaryotic initiation factor 4F: a vulnerability of tumor cells.

Authors:  Teresa Lee; Jerry Pelletier
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

Review 2.  Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks.

Authors:  Brian Magnuson; Bilgen Ekim; Diane C Fingar
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

Review 3.  Hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

Review 4.  Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.

Authors:  Seth A Wander; Bryan T Hennessy; Joyce M Slingerland
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

5.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

6.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.

Authors:  Diego F Calvisi; Chunmei Wang; Coral Ho; Sara Ladu; Susie A Lee; Sandra Mattu; Giulia Destefanis; Salvatore Delogu; Antje Zimmermann; Johan Ericsson; Stefania Brozzetti; Tommaso Staniscia; Xin Chen; Frank Dombrowski; Matthias Evert
Journal:  Gastroenterology       Date:  2010-12-11       Impact factor: 22.682

7.  Blocking eIF4E-eIF4G interaction as a strategy to impair coronavirus replication.

Authors:  Regina Cencic; Marc Desforges; David R Hall; Dima Kozakov; Yuhong Du; Jaeki Min; Raymond Dingledine; Haian Fu; Sandor Vajda; Pierre J Talbot; Jerry Pelletier
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

Review 8.  Targeted therapies for hepatocellular carcinoma.

Authors:  Augusto Villanueva; Josep M Llovet
Journal:  Gastroenterology       Date:  2011-03-13       Impact factor: 22.682

9.  AKT (v-akt murine thymoma viral oncogene homolog 1) and N-Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c-Myc pathways.

Authors:  Coral Ho; Chunmei Wang; Sandra Mattu; Giulia Destefanis; Sara Ladu; Salvatore Delogu; Julia Armbruster; Lingling Fan; Susie A Lee; Lijie Jiang; Frank Dombrowski; Matthias Evert; Xin Chen; Diego F Calvisi
Journal:  Hepatology       Date:  2011-12-19       Impact factor: 17.425

10.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

View more
  36 in total

1.  Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.

Authors:  Lei Li; Li Che; Kevin M Tharp; Hyo-Min Park; Maria G Pilo; Dan Cao; Antonio Cigliano; Gavinella Latte; Zhong Xu; Silvia Ribback; Frank Dombrowski; Matthias Evert; Gregory J Gores; Andreas Stahl; Diego F Calvisi; Xin Chen
Journal:  Hepatology       Date:  2016-03-25       Impact factor: 17.425

2.  Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.

Authors:  Shanshan Zhang; Xinhua Song; Dan Cao; Zhong Xu; Biao Fan; Li Che; Junjie Hu; Bin Chen; Mingjie Dong; Maria G Pilo; Antonio Cigliano; Katja Evert; Silvia Ribback; Frank Dombrowski; Rosa M Pascale; Antonio Cossu; Gianpaolo Vidili; Alberto Porcu; Maria M Simile; Giovanni M Pes; Gianluigi Giannelli; John Gordan; Lixin Wei; Matthias Evert; Wenming Cong; Diego F Calvisi; Xin Chen
Journal:  J Hepatol       Date:  2017-07-19       Impact factor: 25.083

3.  Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans.

Authors:  Lei Li; Giulia M Pilo; Xiaolei Li; Antonio Cigliano; Gavinella Latte; Li Che; Christy Joseph; Marta Mela; Chunmei Wang; Lijie Jiang; Silvia Ribback; Maria M Simile; Rosa M Pascale; Frank Dombrowski; Matthias Evert; Clay F Semenkovich; Xin Chen; Diego F Calvisi
Journal:  J Hepatol       Date:  2015-10-22       Impact factor: 25.083

Review 4.  Ribosomal proteins: insight into molecular roles and functions in hepatocellular carcinoma.

Authors:  X Xie; P Guo; H Yu; Y Wang; G Chen
Journal:  Oncogene       Date:  2017-09-25       Impact factor: 9.867

5.  mTORC2 Signaling Is Necessary for Timely Liver Regeneration after Partial Hepatectomy.

Authors:  Meng Xu; Haichuan Wang; Jingxiao Wang; Deviana Burhan; Runze Shang; Pan Wang; Yi Zhou; Rong Li; Bingyong Liang; Katja Evert; Kirsten Utpatel; Zhong Xu; Xinhua Song; Li Che; Diego F Calvisi; Bruce Wang; Xi Chen; Yong Zeng; Xin Chen
Journal:  Am J Pathol       Date:  2020-02-05       Impact factor: 4.307

6.  Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.

Authors:  Chunmei Wang; Li Che; Junjie Hu; Shanshan Zhang; Lijie Jiang; Gavinella Latte; Maria I Demartis; Junyan Tao; Bing Gui; Maria G Pilo; Silvia Ribback; Frank Dombrowski; Matthias Evert; Diego F Calvisi; Xin Chen
Journal:  Liver Int       Date:  2016-01-30       Impact factor: 5.828

7.  Phospho-inositide-dependent kinase 1 regulates signal dependent translation in megakaryocytes and platelets.

Authors:  Bhanu Kanth Manne; Seema Bhatlekar; Elizabeth A Middleton; Andrew S Weyrich; Oliver Borst; Matthew T Rondina
Journal:  J Thromb Haemost       Date:  2020-03-05       Impact factor: 5.824

8.  A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis.

Authors:  Pin Liu; Mengmeng Ge; Junjie Hu; Xiaolei Li; Li Che; Kun Sun; Lili Cheng; Yuedong Huang; Maria G Pilo; Antonio Cigliano; Giovanni M Pes; Rosa M Pascale; Stefania Brozzetti; Gianpaolo Vidili; Alberto Porcu; Antonio Cossu; Giuseppe Palmieri; Maria C Sini; Silvia Ribback; Frank Dombrowski; Junyan Tao; Diego F Calvisi; Ligong Chen; Xin Chen
Journal:  Hepatology       Date:  2017-05-22       Impact factor: 17.425

9.  Targeted disruption of fibrinogen like protein-1 accelerates hepatocellular carcinoma development.

Authors:  Hamed Nayeb-Hashemi; Anal Desai; Valeriy Demchev; Roderick T Bronson; Jason L Hornick; David E Cohen; Chinweike Ukomadu
Journal:  Biochem Biophys Res Commun       Date:  2015-07-28       Impact factor: 3.575

10.  Ribosomal protein S15a promotes tumor angiogenesis via enhancing Wnt/β-catenin-induced FGF18 expression in hepatocellular carcinoma.

Authors:  Pengyi Guo; Yi Wang; Chunxiu Dai; Chonglin Tao; Fang Wu; Xiaozai Xie; Haitao Yu; Qiandong Zhu; Junjian Li; Longyun Ye; Fuxiang Yu; Yunfeng Shan; Zhengping Yu; Renumathy Dhanasekaran; Rongyuan Zheng; Gang Chen
Journal:  Oncogene       Date:  2017-12-15       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.